FierceBiotechOriginal article
{"a":[{"_":"SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launch","$":{"href":"/biotech/sk-biopharma-pens-795m-deal-usher-biohavens-epilepsy-therapy-towards-fda","hreflang":"en"}}]}
PartnershipKv7 ion channel activatorPositive
AI Analysis
Summary
SK Biopharmaceuticals agreed to pay $350 million upfront to Biohaven to develop and commercialize a Kv7 ion channel activator for epilepsy, with a total deal value of $795 million and a targeted launch in 2029.
Outcome Details
$350M upfront payment for development and commercialization rights
Importance:7/10
Sentiment:
0.60
licensing dealepilepsyion channelpartnership
Read the original article
Published by FierceBiotech on August 26, 2026 4:48 AM